Novartis division Sandoz recalls one lot of blood pressure drug

Novartis said on Thursday its Sandoz division was recalling one lot of losartan tablets after finding traces of a probable carcinogen in the blood pressure drug.

The drug is made by China’s Zhejiang Huahai Pharmaceutical Co Ltd. Last month, the European Medicines Agency placed the firm under high supervision after a probable carcinogen was found in its blood pressure drug valsartan.

A review was extended to other ‘sartan’ medicines, including candesartan, irbesartan, losartan, olmesartan and valsartan, after very low levels of a carcinogen was found in losartan made by Hetero Labs in India.

Novartis said Sandoz had not received any reports of adverse events related to this lot.

(Reporting by Arunima Banerjee in Bengaluru; Editing by Chris Reese)

  • Related Posts

    Piyush Goyal meets pharma industry leaders to discuss R&D, competitiveness boost

    New Delhi: Union Commerce and Industry Minister Piyush Goyal has discussed strategies to boost competitiveness and strengthen research and development activities with the business representatives of the pharmaceutical industry. “Had…

    Senores Pharma to Buy Two Teva ANDAs

    Mumbai, August 14, 2025 — Senores Pharmaceuticals will acquire two abbreviated new drug applications (ANDAs) from Teva Pharmaceuticals USA. The deal is Senores’ third US move in six months, underscoring…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Piyush Goyal meets pharma industry leaders to discuss R&D, competitiveness boost

    Piyush Goyal meets pharma industry leaders to discuss R&D, competitiveness boost

    Senores Pharma to Buy Two Teva ANDAs

    Senores Pharma to Buy Two Teva ANDAs

    Lab-grown rabies antibodies show promise as cheaper, safer alternative

    Lab-grown rabies antibodies show promise as cheaper, safer alternative

    Lilly launches Mounjaro KwikPen in India

    Lilly launches Mounjaro KwikPen in India